TLSA
Tiziana Life Sciences Ltd
Company Overview
| Mkt Cap | $192.83M | Price | $1.78 |
| Volume | 1.23M | Change | +3.49% |
| P/E Ratio | -16.3 | Open | $1.71 |
| Revenue | -- | Prev Close | $1.72 |
| Net Income | $-11.9M | 52W Range | $0.63 - $2.60 |
| Div Yield | N/A | Target | $3.00 |
| Overall | 30 | Value | -- |
| Quality | 34 | Technical | 27 |
No chart data available
About Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
Latest News
Tiziana Life Sciences Initiates Phase 2 Alzheimer’s Trial with Innovative Approach
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TLSA | $1.78 | +3.5% | 1.23M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Tiziana Life Sciences Ltd Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW